Screening In-Depth Focus 2017
Included in this Screening In-Depth Focus: Phenotypic and target-based screening; Killing cancer cells using clinical drug resistance; Inflammatory biomarkers as a herbal anti-arthritic drug discovery tool...
List view / Grid view
Articles
Insights from discovery through clinical efficacy to support a new class of therapeutics in Alzheimer’s disease
Research into innovative small molecule therapeutics with disease modifying potential in Alzheimer’s disease (AD) has been conducted at Alzheon since 2013.
Using native mass spectrometry to inform drug discovery
Mass spectrometry (MS) performed under native-like conditions (nMS) is a promising approach for studying protein-drug interactions, and has already informed treatments of some of the most intractable diseases including cancer, diabetes and Alzheimer’s.
Review: Biomarkers towards personalised therapy in cancer
Since the sequence of the human genome was published some 20 years ago, omics strategies have enabled the generation of detailed molecular signatures of cancers and their subtypes.
Drug Target Review – Issue #2 2017
Included in this issue: Technology convergence improves testing; Screening; Stem Cells; Targets; Mass Spectrometry; and Therapeutics in Alzheimer's disease...
3D bioprinting – from science fiction to reality?
The global 3D bioprinting market is predicted to reach $1.8 billion in revenue by 2027. IDTechEx's Dr Nadia Tsao explains why...
Creating the ‘google earth’ of tumours
We caught up with Dr Josephine Bunch to find out how NPL are using the Cancer Research Grand Challenge funding & novel imaging techniques to map cancer tumours...
A new approach to Organ-on-a-Chip
Draper's Joe Charest explains how synthetic organoids can lead to safer drug testing, and why organ-on-a-chip technology is the future of drug discovery...
GSK: A Lifetime in Fluorescence
GSK's top investigators explain why the data quality offered by Fluorescence lifetime detection technology for drug discovery applications is superior…
Fast-tracking the approach to drug discovery and development
Mundipharma EDO GmbH's Dr Thomas Mehrling talks through the benefits of streamlining the drug discovery and development process using the EDO model...
Deadly bite: How Venomab’s novel research is tackling the global antivenom shortage
We caught up with Andreas Laustsen Co-Founder and CEO of Venomab, to find the latest in antivenom research…
Under the microscope with Labcyte
Dr Sheraz Gul, Head of Assay Development and Screening at the Fraunhofer Institute for Molecular Biology and Applied Ecology, answers questions on assay procedures...
Assays In-Depth Focus 2017
HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole animal screening assay formats. Horst Flotow, from Hit Discovery Constance, discusses the benefits and practicalities of, and recent progress in, whole animal screening. Madhu Lal-Nag, National Center for Advancing Translational Sciences, and Anton…
Biomarkers In-Depth Focus 2017
Drug developers sometimes think of imaging as an emerging discipline. But John Waterton, Paul Hockings, Juliana Maynard and Caleb Roberts explain how imaging biomarkers are transforming drug development. Francesco Gatto and Jens Nielsen, from the Chalmers University of Technology in Sweden, discuss moving towards systems biomarkers for cancer diagnosis...
Antibodies In-Depth Focus 2017
Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy...